We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
Read MoreHide Full Article
Key Takeaways
Glaukos licenses RevOpsis' RO-104 and RevMod platform to expand its retinal disease treatment pipeline.
RO-104 targets VEGF-A, VEGF-C and Ang-2, demonstrating superior efficacy in preclinical animal models.
The RevMod platform enables GKOS to develop up to four additional biologics for multiple retinal diseases.
Glaukos Corporation (GKOS - Free Report) recently announced a licensing agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, an investigational tri-specific biologic for multiple retinal diseases. The agreement grants Glaukos exclusive rights to RevOpsis’ RevMod platform to discover and develop up to four additional retinal biologic candidates.
Glaukos chairman and CEO Thomas Burns said that the addition of RO-104 and exclusive access to the RevMod platform marks a strategic step in expanding the company’s retinal franchise and complements its existing retinal R&D initiatives. The agreement strengthens GKOS’ pipeline with a first-in-class tri-specific biologic and offers an opportunity to develop additional therapeutic candidates for multiple retinal diseases. Management believes RO-104’s ability to inhibit three angiogenic pathways simultaneously could provide significant treatment advantages for retinal vascular diseases while supporting the company’s long-term innovation strategy in the retina market.
GKOS Stock Trend Following the News
Following the announcement, GKOS stock lost 6.3% at yesterday’s close. Year to date, the stock gained 42.8%, outperforming the industry’s 6.9% decline and the S&P 500’s 13.9% gain.
The agreement could strengthen GKOS’ long-term growth prospects by expanding its presence in retinal therapeutics beyond its existing ophthalmic business. Access to a differentiated biologic candidate and a discovery platform may diversify its future product opportunities and create additional avenues for growth. If RO-104 demonstrates clinical success, it could help Glaukos compete in multiple retinal disease markets, while the platform’s additional candidates could provide further pipeline value over time.
GKOS currently has a market capitalization of $10.16 billion.
Image Source: Zacks Investment Research
More on the News
RO-104 is designed as a first-in-class tri-specific biologic with a high-concentration formulation that inhibits VEGF-A, VEGF-C and Ang-2, three clinically validated pathways involved in the progression of retinal vascular diseases. It is being developed for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR) and retinal vein occlusion (RVO). In established preclinical animal models, the candidate has demonstrated superior efficacy compared with approved anti-VEGF therapies.
Beyond RO-104, the license gives Glaukos exclusive rights to the RevMod platform across geographic atrophy, DME, DR, RVO and nAMD, enabling the discovery and development of up to four additional next-generation retinal biologics. The financial terms of the agreement were not disclosed. Clinical development and regulatory progress will be important milestones in determining the commercial potential of these programs.
RevOpsis management views the agreement as validation of its RevMod platform and its strategy of developing next-generation multispecific therapies for retinal diseases. The company believes Glaukos’ ophthalmology expertise and commercialization capabilities will help advance RO-104 and expand the platform into a broader portfolio of potential retinal treatments.
Industry Prospects Favoring the Market
According to Fortune Business Insights, the global retinal biologics market is estimated to reach $27.25 billion in 2026 and is projected to grow at a CAGR of 8% through 2034.
Factors like rising rates of retinal disorders, an aging population, increasing diabetes prevalence and advances in targeted biologic therapies are expected to support market growth.
Other News
Glaukos recently announced positive Phase 3 extension study results for Epioxa, demonstrating durable benefits three years after a single treatment. Patients showed sustained corneal improvement, meaningful visual acuity gains and a favorable safety profile, supporting Epioxa’s potential to provide long-term keratoconus stabilization.
Last month, Glaukos launched its “Could it be KC?” campaign, partnering with NBA champion Stephen Curry to raise awareness of keratoconus, a progressive corneal disease. Curry will share his personal experience to encourage early detection, proactive eye care and timely diagnosis, with educational initiatives targeting patients, families and underserved communities.
Some other top-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.1%.
View the Zacks #1 Rank List
Image: Bigstock
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
Key Takeaways
Glaukos Corporation (GKOS - Free Report) recently announced a licensing agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, an investigational tri-specific biologic for multiple retinal diseases. The agreement grants Glaukos exclusive rights to RevOpsis’ RevMod platform to discover and develop up to four additional retinal biologic candidates.
Glaukos chairman and CEO Thomas Burns said that the addition of RO-104 and exclusive access to the RevMod platform marks a strategic step in expanding the company’s retinal franchise and complements its existing retinal R&D initiatives. The agreement strengthens GKOS’ pipeline with a first-in-class tri-specific biologic and offers an opportunity to develop additional therapeutic candidates for multiple retinal diseases. Management believes RO-104’s ability to inhibit three angiogenic pathways simultaneously could provide significant treatment advantages for retinal vascular diseases while supporting the company’s long-term innovation strategy in the retina market.
GKOS Stock Trend Following the News
Following the announcement, GKOS stock lost 6.3% at yesterday’s close. Year to date, the stock gained 42.8%, outperforming the industry’s 6.9% decline and the S&P 500’s 13.9% gain.
The agreement could strengthen GKOS’ long-term growth prospects by expanding its presence in retinal therapeutics beyond its existing ophthalmic business. Access to a differentiated biologic candidate and a discovery platform may diversify its future product opportunities and create additional avenues for growth. If RO-104 demonstrates clinical success, it could help Glaukos compete in multiple retinal disease markets, while the platform’s additional candidates could provide further pipeline value over time.
GKOS currently has a market capitalization of $10.16 billion.
Image Source: Zacks Investment Research
More on the News
RO-104 is designed as a first-in-class tri-specific biologic with a high-concentration formulation that inhibits VEGF-A, VEGF-C and Ang-2, three clinically validated pathways involved in the progression of retinal vascular diseases. It is being developed for neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), diabetic retinopathy (DR) and retinal vein occlusion (RVO). In established preclinical animal models, the candidate has demonstrated superior efficacy compared with approved anti-VEGF therapies.
Beyond RO-104, the license gives Glaukos exclusive rights to the RevMod platform across geographic atrophy, DME, DR, RVO and nAMD, enabling the discovery and development of up to four additional next-generation retinal biologics. The financial terms of the agreement were not disclosed. Clinical development and regulatory progress will be important milestones in determining the commercial potential of these programs.
RevOpsis management views the agreement as validation of its RevMod platform and its strategy of developing next-generation multispecific therapies for retinal diseases. The company believes Glaukos’ ophthalmology expertise and commercialization capabilities will help advance RO-104 and expand the platform into a broader portfolio of potential retinal treatments.
Industry Prospects Favoring the Market
According to Fortune Business Insights, the global retinal biologics market is estimated to reach $27.25 billion in 2026 and is projected to grow at a CAGR of 8% through 2034.
Factors like rising rates of retinal disorders, an aging population, increasing diabetes prevalence and advances in targeted biologic therapies are expected to support market growth.
Other News
Glaukos recently announced positive Phase 3 extension study results for Epioxa, demonstrating durable benefits three years after a single treatment. Patients showed sustained corneal improvement, meaningful visual acuity gains and a favorable safety profile, supporting Epioxa’s potential to provide long-term keratoconus stabilization.
Last month, Glaukos launched its “Could it be KC?” campaign, partnering with NBA champion Stephen Curry to raise awareness of keratoconus, a progressive corneal disease. Curry will share his personal experience to encourage early detection, proactive eye care and timely diagnosis, with educational initiatives targeting patients, families and underserved communities.
Glaukos Corporation Price
Glaukos Corporation price | Glaukos Corporation Quote
GKOS’ Zacks Rank & Other Key Picks
Currently, GKOS carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.1%.